J2 Capital Management Inc Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

J2 Capital Management Inc bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,068 shares of the medical equipment provider's stock, valued at approximately $397,000.

A number of other large investors also recently modified their holdings of LNTH. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after buying an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. increased its holdings in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares during the last quarter. Foundry Partners LLC grew its stake in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 133 shares in the last quarter. Finally, Moody National Bank Trust Division raised its stake in shares of Lantheus by 1.0% during the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after purchasing an additional 141 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Up 2.6%

Shares of NASDAQ:LNTH traded up $2.02 during trading on Wednesday, hitting $79.71. The stock had a trading volume of 459,291 shares, compared to its average volume of 991,854. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company has a market capitalization of $5.51 billion, a PE ratio of 13.26 and a beta of 0.23. The firm's fifty day moving average is $91.26 and its 200 day moving average is $91.71.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.69 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent research reports. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Transactions at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.